Research Reports in Clinical Cardiology最新文献_第9页

Periprocedural myocardial infarction enhances the predictive value of inflammatory biomarkers for patients with obstructive coronary artery disease after implantation of drug-eluting stent 围手术期心肌梗死增强了炎症生物标志物对冠脉阻塞性疾病患者药物洗脱支架植入术后的预测价值

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2015-02-18 DOI: 10.2147/RRCC.S78173

Anastasia Jesika, Zuo-ying Hu, J. Kan, Shao‐Liang Chen

{"title":"Periprocedural myocardial infarction enhances the predictive value of inflammatory biomarkers for patients with obstructive coronary artery disease after implantation of drug-eluting stent","authors":"Anastasia Jesika, Zuo-ying Hu, J. Kan, Shao‐Liang Chen","doi":"10.2147/RRCC.S78173","DOIUrl":"https://doi.org/10.2147/RRCC.S78173","url":null,"abstract":"Objective: The present study aims to clarify the long-term clinical importance of interleukin (IL)-6 in predicting major adverse cardiac events (MACE) for an entire cohort of patients with coronary artery disease after implantation of a drug-eluting stent (DES), and its interplay with periprocedural myocardial infarction (PMI). Background: The correlation of proinflammatory biomarkers with occurrence of clinical events, including PMI and mortality, is controversial. Methods: IL-6 was measured in 1,991 patients at admission. The participants were then assigned to two groups: IL-6 level $ 9 pg/mL and IL-6 level , 9 pg/mL. The primary endpoint was the occurrence of cardiac death or myocardial infarction (MI) at year 3 after indexed percutaneous coronary intervention (PCI) procedure. Results: The in-hospital rate of the primary endpoint in the IL-6 level $ 9 pg/mL group was 9.1%, statistically significantly different to 6.3% in the IL-6 , 9 pg/mL group ( P = 0.026), mainly driven by the increased rate of MI (9.1% vs 6.1%, P = 0.025). Those differences in MI/death and MI was sustained through to the 3-year follow-up (10.9% vs 7.6%, P = 0.017 and 10.1% vs 7.5%, P = 0.049). At the 3-year follow-up after the assigned procedure, more frequent MI was also the main reason for increased composite MACE between the IL-6 $ 9 pg/mL and IL-6 , 9 pg/mL groups (20.7% vs 15.8%, P = 0.007) . In the IL-6 $ 9 pg/mL group, PMI was strongly correlated with mortality at 1-year through to the 3-year (hazard ratio: 2.96, 95% confidence interval: 1.35–6.49, P = 0.005) follow-up after PCI procedure. Conclusion: Elevated preprocedural serum IL-6 level was correlated with death, MI, and MACE after implantation of the DES. PMI enhances the predictive value of IL-6 for post-DES events.","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"6 1","pages":"17-28"},"PeriodicalIF":0.4,"publicationDate":"2015-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S78173","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68475961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrial fibrillation and its influence on stroke risk 心房颤动及其对卒中风险的影响

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2015-02-09 DOI: 10.2147/RRCC.S54209

D. Prisco, Caterina Cenci, E. Silvestri, L. Ciucciarelli, B. Tomberli, C. Tamburini

引用次数: 2

Current perspectives on cardioembolic ischemic stroke in very old patients 高龄患者心脏栓塞性缺血性脑卒中的现状

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-12-22 DOI: 10.2147/RRCC.S45809

A. Arboix, J. Massons, J. Alió

引用次数: 2

The Freedom SOLO bovine pericardial stentless valve Freedom SOLO牛心包无支架瓣膜

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-12-02 DOI: 10.2147/RRCC.S72978

O. Stanger, H. Tevaearai, T. Carrel

{"title":"The Freedom SOLO bovine pericardial stentless valve","authors":"O. Stanger, H. Tevaearai, T. Carrel","doi":"10.2147/RRCC.S72978","DOIUrl":"https://doi.org/10.2147/RRCC.S72978","url":null,"abstract":"Abstract: The third-generation bovine pericardium Freedom SOLO (FS) stentless valve emerged in 2004 as a modified version of the Pericarbon Freedom stentless valve and as a very attractive alternative to stented bioprostheses. The design, choice of tissue, and anticalcification treatment fulfill most, if not all, requirements for an ideal valve substitute. The FS combines the single-suture, subcoronary implantation technique with the latest-generation bovine pericardial tissue and novel anticalcification treatment. The design allows imitation of the native healthy valve through unrestricted adaption to the patient's anatomy, reproducing a normal valve/root complex. However, despite hemodynamic performance superior to stented valves, we are approaching a critical observation period as superior durability, freedom from structural valve deterioration, and nonstructural failure has not been proven as expected. However, optimal performance and freedom from structural valve deterioration depend on correct sizing and perfect symmetric implantation, to ensure low leaflet stress. Any malpositioning can lead to tissue fatigue over time. Furthermore, the potential for better outcomes depends on optimal patient selection and observance of the limitations for the use of stentless valves, particularly for the FS. Clearly, stentless valve implantation techniques are less reproducible and standardized, and require surgeon-dependent experience and skill. Regardless of whether or not stentless valve durability surpasses third-generation stented bioprostheses, they will continue to play a role in the surgical repertoire. This review intends to help practitioners avoid pitfalls, observe limitations, and improve patient selection for optimal long-term outcome with the attractive FS stentless valve.","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"5 1","pages":"349-361"},"PeriodicalIF":0.4,"publicationDate":"2014-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S72978","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68475168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Myocardial T1 mapping: where are we now and where are we going? 心肌T1映射:我们现在在哪里，我们要去哪里?

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-11-26 DOI: 10.2147/RRCC.S50891

A. Abdel‐Gadir, T. Treibel, James C. Moon

引用次数: 4

Fluctuant tonus of the coronary arteries possibly documented by repeated multidetector row computed tomography 冠状动脉张力波动可能由多次多排计算机断层扫描记录

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-11-26 DOI: 10.2147/RRCC.S72464

Ikuko Anan, K. Hongo, M. Kawai, Kazuo Ogawa, T. Sakuma, K. Fukuda, I. Taniguchi, M. Yoshimura

{"title":"Fluctuant tonus of the coronary arteries possibly documented by repeated multidetector row computed tomography","authors":"Ikuko Anan, K. Hongo, M. Kawai, Kazuo Ogawa, T. Sakuma, K. Fukuda, I. Taniguchi, M. Yoshimura","doi":"10.2147/RRCC.S72464","DOIUrl":"https://doi.org/10.2147/RRCC.S72464","url":null,"abstract":"Objective: Recent advances in multidetector row computed tomography (MDCT) have made it possible to diagnose coronary stenosis with high sensitivity. However, coronary arterial tonus has not been considered when reading MDCT. We hypothesized that MDCT can document fluctuant tonus of the coronary arteries. Methods: The study population consisted of 39 consecutive patients who underwent MDCT twice in our institution with 64-row dual-source MDCT. Measurements were performed with stretched multiplanar reconstruction images using the full width at half maximum method. The coronary arteries were measured at each segment, and the same measurement was performed in the ascending aorta and the left internal thoracic artery (ITA). The percent diameter changes between the first and second measurements were examined in each segment of the coronary arteries and compared with those in the aorta or the ITA. Results: The average percent diameter changes were statistically equivalent between the coronary arteries and the aorta or the ITA. On the other hand, the percent diameter changes in distribution were significantly larger in the coronary arteries than those in the aorta or the ITA. This suggests that the diameter of the coronary arteries is liable to show variation compared to that of other arteries. Conclusion: This study confirmed for the first time that coronary arteries can fluctuate sub-stantially and that these changes can be documented by MDCT. Changes in coronary arterial tonus should therefore be considered when reading MDCT. row computed tomography; CCB, calcium channel blocker; aCe-i, angiotensin-converting enzyme inhibitor; isDn, isosorbide dinitrate.","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"5 1","pages":"327-337"},"PeriodicalIF":0.4,"publicationDate":"2014-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S72464","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68475030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac cachexia and muscle wasting: definition, physiopathology, and clinical consequences 心脏恶病质和肌肉萎缩:定义、生理病理和临床后果

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-11-13 DOI: 10.2147/RRCC.S41513

M. Okoshi, F. Romeiro, P. Martinez, S. A. Oliveira, B. Polegato, K. Okoshi

{"title":"Cardiac cachexia and muscle wasting: definition, physiopathology, and clinical consequences","authors":"M. Okoshi, F. Romeiro, P. Martinez, S. A. Oliveira, B. Polegato, K. Okoshi","doi":"10.2147/RRCC.S41513","DOIUrl":"https://doi.org/10.2147/RRCC.S41513","url":null,"abstract":": Cachexia and muscle wasting are frequently observed in heart failure patients. Cachexia is a predictor of reduced survival, independent of important parameters such as age, heart failure functional class, and functional capacity. Muscle and fat wasting can also predict adverse outcome during cardiac failure. Only more recently were these conditions defined in International Consensus. Considering that heart failure is an inflammatory disease, cardiac cachexia has been diagnosed by finding a body weight loss . 5%, in the absence of other diseases and independent of other criteria. Muscle wasting has been defined as lean appendicular mass corrected for height squared of 2 standard deviations or more below the mean for healthy individuals between 20 years and 30 years old from the same ethnic group. The etiology of heart failure-associated cachexia and muscle wasting is multifactorial, and the underlying physiopathological mechanisms are not completely understood. The most important factors are reduced food intake, gastrointestinal alterations, immunological activation, neurohormonal abnormalities, and an imbalance between anabolic and catabolic processes. Cachexia and muscle wasting have clinical consequences in several organs and systems including the gastrointestinal and erythropoietic systems, and the heart, previously affected by the primary disease. We hope that a better understanding of the mechanisms involved in their physiopathology will allow the development of pharmacological and nonpharmacological therapies to effectively prevent and treat heart failure-induced cachexia and muscle wasting before significant body weight and muscle wasting occurs.","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"5 1","pages":"319-326"},"PeriodicalIF":0.4,"publicationDate":"2014-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S41513","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68472819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

individualized cardiac resynchronization therapy: current status 个体化心脏再同步化治疗:现状

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-11-07 DOI: 10.2147/RRCC.S50541

M. Ruwald, N. Bruun

{"title":"individualized cardiac resynchronization therapy: current status","authors":"M. Ruwald, N. Bruun","doi":"10.2147/RRCC.S50541","DOIUrl":"https://doi.org/10.2147/RRCC.S50541","url":null,"abstract":"Cardiac resynchronization therapy (CRT) has shown a substantial reduction in heart failure patient morbidity and mortality, with improvement in quality of life as well as symptoms. The therapy is, however, limited to approximately 10%-15% of heart failure patients and, typi- cally, 30% do not derive benefit from the device. For optimal outcomes with CRT, the correct selection of patients is of paramount importance. The first parameter is depressed left ventricular systolic function, and the second is a wide QRS complex. Different nuances among clinical tri- als have rendered guidelines pragmatic and compromising, but also conflicting and confusing. A large proportion of real-life CRTs are implanted in patients where the evidence for benefit is scarce or not present. Further, for optimal benefit, patients require evidence-directed medi - cal therapy at maximal doses, effective placement of ventricular leads, and high biventricular pacing percentages, along with optimized atrioventricular (AV) and interventricular interval device programming. These items, as well as specific clinical characteristics, such as AV block and atrial fibrillation, in the context of CRT indications, are discussed. This review focuses on these issues to guide the clinician through guidelines, with an evidence-based update on the current status of CRT.","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"17 1","pages":"305-317"},"PeriodicalIF":0.4,"publicationDate":"2014-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S50541","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68473649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Takotsubo cardiomyopathy: etiology, diagnosis, and optimal management Takotsubo心肌病:病因、诊断和最佳治疗

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-10-29 DOI: 10.2147/RRCC.S46021

S. Wan, J. Liang

引用次数: 4

Role of vitamins in cardiovascular health and disease 维生素在心血管健康和疾病中的作用

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-10-24 DOI: 10.2147/RRCC.S44465

B. Debreceni, L. Debreceni

{"title":"Role of vitamins in cardiovascular health and disease","authors":"B. Debreceni, L. Debreceni","doi":"10.2147/RRCC.S44465","DOIUrl":"https://doi.org/10.2147/RRCC.S44465","url":null,"abstract":"Cardiovascular disease (CVD) is the leading cause of mortality around the world. The prevention of CVD is a main goal of health care. Vitamins, especially those with antioxidant potency, may have a role in the prevention of and therapy for CVD. Antioxidant vitamins, vitamin C, vitamin E, and carotenoids are able to decrease the rate of oxidative stress, which may have a principal role in the pathogenesis of atherosclerosis and CVD. Vitamin B 6 , vitamin B 12 , and folic acid, as well as vitamin D, also contribute to maintenance of cardiovascular health and can induce cardioprotective effects. Although most of the randomized controlled trials on vitamins failed to show the benefit of vitamin supplementation for cardiovascular outcomes, a number of observational and cohort studies, meta-analyses, and stratified analyses of large vitamin trials appeared to show an effect in some aspects of cardiovascular prevention. Moreover, many of the vitamin trials for secondary prevention are biased by use of vitamins and drugs effective for cardiovascular prevention; therefore, the conclusions drawn from them supporting the effectiveness of vitamin substitution for the prevention of CVD may be inappropriate. To summarize, there are abundant data suggesting the role of vitamins in cardiovascular health and in the primary prevention of CVD; however, examinations using new concepts and new study designs are needed to establish the effectiveness of vitamin supplementation in the therapy for","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"5 1","pages":"283-295"},"PeriodicalIF":0.4,"publicationDate":"2014-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S44465","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68472565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7